Statements (69)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:castle
|
| gptkbp:accessories |
rarely reported
|
| gptkbp:activities |
IL-6 inhibition
neutralizes IL-6 |
| gptkbp:affects |
not fully understood
|
| gptkbp:appointed_by |
intravenous infusion
|
| gptkbp:approves |
gptkb:multicentric_Castleman_disease
gptkb:2014 |
| gptkbp:availability |
prescription only
|
| gptkbp:class |
immunomodulator
|
| gptkbp:clinical_trial |
Phase II
oncology multiple trials NC T01024036 for other indications |
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:combatants |
high affinity for IL-6
|
| gptkbp:contraindication |
active infections
|
| gptkbp:defense_mechanism |
possible
|
| gptkbp:developed_by |
gptkb:Janssen_Biotech
|
| gptkbp:dosage_form |
solution for infusion
|
| gptkbp:duration |
varies by patient
every 3 weeks |
| gptkbp:education |
important for understanding treatment
|
| gptkbp:feedback |
generally positive
|
| gptkbp:formulation |
sterile solution
|
| gptkbp:healthcare |
April 2014
important for prescribing |
| https://www.w3.org/2000/01/rdf-schema#label |
siltuximab
|
| gptkbp:indication |
treatment of Castleman disease
|
| gptkbp:ingredients |
C6420 H9920 N1716 O1984 S44
|
| gptkbp:interacts_with |
limited interactions
|
| gptkbp:invention |
patented
|
| gptkbp:is_a_source_of |
recombinant DNA technology
|
| gptkbp:is_effective_against |
improved outcomes in Castleman disease
|
| gptkbp:is_monitored_by |
required during treatment
blood counts |
| gptkbp:manager |
intravenous
|
| gptkbp:market |
gptkb:2014
|
| gptkbp:marketed_as |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:name |
WHO Model List of Essential Medicines
|
| gptkbp:pharmacokinetics |
monoclonal antibody pharmacokinetics
IL-6 receptor blockade |
| gptkbp:population |
adults
|
| gptkbp:price |
high
|
| gptkbp:provides_information_on |
included in treatment guidelines
|
| gptkbp:receives_funding_from |
funded by pharmaceutical company
|
| gptkbp:recruitment |
based on diagnosis
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research |
ongoing studies
|
| gptkbp:research_areas |
autoimmune diseases
|
| gptkbp:safety_features |
post-marketing surveillance
generally well tolerated collected post-marketing |
| gptkbp:scholarships |
available through manufacturer programs
|
| gptkbp:side_effect |
increased risk of infection
hypersensitivity reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:supply_chain |
managed by manufacturer
|
| gptkbp:targets |
gptkb:interleukin-6
|
| gptkbp:traded_on |
gptkb:Sylvant
|
| gptkbp:treatment |
monitored regularly
disease control evaluated in studies |
| gptkbp:type_of_care |
important for efficacy
|
| gptkbp:type_of_insurance |
varies by plan
|
| gptkbp:weight |
146 k Da
|